1. An allogeneic immunotherapeutic agent for the treatment of prostate cancer comprising three human prostate cell lines from three different sources, of which one, two or three cell lines are derived from normal tissue(s), wherein each said normal tissue(s) is (are) from a source which is a non-cancerous prostate.

2. An immunotherapeutic agent for the treatment of prostate cancer according to claim 1, comprising three human prostate cell lines of which one cell line is derived from normal tissue and the other two cell lines are derived from tumour tissues.

3. An immunotherapeutic agent for the treatment of prostate cancer according to claim 1, comprising three human prostate cell lines of which two cell lines are derived from normal tissue and the other cell line is derived from a tumour tissue.

4. An immunotherapeutic agent of claims 1, 2 and 3 where the lines derived from normal tissue are chosen from from PNT1A (ECACC Ref No: 95012614) or PNT2 (ECACC Ref No: 95012613)

5. An immunotherapeutic agent of claims 1, 2 and 3 where the line(s) derived from tumour tissue is/are chosen from NIH1519-CPTX, NIH1532-CP2TX, NIH1535-CP1TX, NIH1542-CP3TX, CA-HPV-10, LnCap, DU145 or PC3.

6. An immunotherapeutic agent for the treatment of prostate cancer comprising three cell lines, namely PNT2, NIH1542-CP3TX andDU145.

7. An immunotherapeutic agent for the treatment of prostate cancer comprising three cell lines, namely PNT2, NIH1542-CP3TX and LnCap.

8. An immunotherapeutic agent for the treatment of prostate cancer comprising three cell lines, namely PNT2, DU145 and LnCap.

9. An immunotherapeutic agent of claims 1-8 wherein the tumour cell lines have been irradiated at 50 to 300 Gy.

10. An immunotherapeutic agent of claims 1-8 wherein the tumour cell lines have been irradiated at 100 to 150 Gy.

11. An allogeneic immunogenic composition comprising an immunotherapeutic agent of claims 1-10 combined with a vaccine adjuvant selected from mycobacterial preparations such as BCG or M. Vaccae, Tetanus toxoid, Diphtheria toxoid, Bordetella Pertussis, interleukin 2, interleukin 12, interleukin 4, interleukin 7, Complete Freund's Adjuvant, Incomplete Freund's Adjuvant or other non-specific agents adjuvant.

12. An immunogenic composition comprising an immunotherapeutic agent of claims 1-10 combined with a vaccine adjuvant selected from mycobacterial preparations such as BCG or M. Vaccae.

13. An immunotherapeutic agent or composition of claims 1-12 wherein the cells are formulated with a cryoprotectant solution including but not limited to 10-30% v/v

aqueous glycerol solution, 5-20% v/v dimethyl sulphoxide or 5-20% w/v human serum albumin either as single cryoprotectants or in combination.

14. An immunotherapeutic agent or composition of claims 1-12 wherein the cells are formulated with a cryoprotectant solution including 5-20% v/v dimethyl sulphoxide and 5-20% w/v human serum albumin in combination.

15. An immunotherapeutic agent or composition of claims 1-14 that induces an immune response in patients characterised by activation of immune T-cells.

16. An immunotherapeutic agent or composition of claims 1-14 that induces an immune response in patients characterised by induction of antibody production.

17. An immunotherapeutic agent or composition of claims 1-14 that induces a decrease in the rate of rise or a decline in the level of serum PSA in prostate cancer patients.

B2

18. An immunotherapeutic agent or composition according to claims 1 to 17 that is administered intradermally.

19. An immunotherapeutic agent or composition according to claims 1 to 17 that is administered intra-prostatically.

20. An allogeneic immunotherapeutic vaccine composition for the treatment of prostate cancer, which comprises or consists of an agent according to any preceding claim together with a physiologically acceptable excipient, adjuvant or carrier.

21. An allogeneic method of prophylaxis or treatment of prostate cancer, which includes administering to a patient an agent or composition according to any preceding claim in one or more doses in suitable dosage form.

22. Use of an agent according to any of claims 1 to 10 in the manufacture of a medicament for the allogeneic treatment of human prostate cancer.